evaluate efficacy of intranasal Montelukast on the outcome of asthma attack in childre

Phase 2

Recruiting

• Conditions: Severe asthma attack.; Severe persistent asthma; J45.5

• Registration Number: IRCT20220119053760N2
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Children 2 to 12 years old
Hospitalization due to an acute asthma attack with a pulmonary index score (PIS) between 7 and 11 (moderate attack) or a score greater than 12 (severe attack)

Exclusion Criteria

Simultaneous treatment with systemic corticosteroids or antileukotrienes within 4 weeks before admission
Other possible causes for the patient's symptoms such as pneumonia
Having a history of chronic lung diseases and anatomical airway problems and congenital heart disease
History of taking anticonvulsant and immunosuppressive drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The severity of the asthma attack. Timepoint: On the first day of hospitalization, every 4 hours and on the following days of hospitalization, once a day, patients based on PIS score (pulmonary index score). Method of measurement: According to the reference, a moderate attack is defined based on the need for auxiliary oxygen-nebulizer albuterol and systemic glucocorticoid, and a severe attack is defined based on the need for auxiliary oxygen-nebulizer salbutamol and ipratropium-systemic glucocorticoid-magnesium sulfate.